title: Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients.
abstract: It has been recently suggested that in Alzheimer disease (AD), the current available therapy with cholinesterase inhibitors (ChEIs) influences platelets amyloid precursor protein (APP) metabolism towards the nonamyloidogenic pathway. In order to investigate whether ChEIs may exert a protective role on vascular damage due to abeta deposition, several parameters of coagulation and fibrinolysis were assessed. Twenty patients with mild AD and 30 age-matched controls entered the study. All subjects performed a multidimensional neuropsychological assessment and a laboratory protocol. Individuals with vascular risk factors and systemic diseases were excluded. In mild AD patients, increased levels of markers of endothelial dysfunction, such as thrombomodulin (TM) and sE-selectin (sE-sel), were seen. After 1-month ChEIs treatment, a significant reduction of TM (p<0.05) and sE-sel (p<0.05) values towards the normal range was observed. These findings suggest that endothelial-related ChEIs action might contribute to the clinical efficacy in AD, slowing down pathology progression.
authors.affiliation: Department of Medical Sciences, Neurological Clinic, University of Brescia, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Borroni
authors.forename: Chiara
authors.initials: C
authors.lastname: Agosti
authors.forename: Giuliana
authors.initials: G
authors.lastname: Martini
authors.forename: Roberta
authors.initials: R
authors.lastname: Volpi
authors.forename: Cristina
authors.initials: C
authors.lastname: Brambilla
authors.forename: Luigi
authors.initials: L
authors.lastname: Caimi
authors.forename: Monica
authors.initials: M
authors.lastname: Di Luca
authors.forename: Alessandro
authors.initials: A
authors.lastname: Padovani
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D000077265:Donepezil; D004730:Endothelium, Vascular / Q000473:pathology*; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008297:Male; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil